Astrocytic inclusions in epilepsy: expanding the spectrum of filaminopathies

Lili-Naz Hazrati1, B K Kleinschmidt-DeMasters, Michael H Handler

  • 1Division of Pathology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada.

Insights

Unique astrocytic inclusions, linked to filamin A, were found in pediatric epilepsy patients. This suggests a spectrum of neurological disorders, potentially termed "filaminopathy," ranging from epilepsy to Aicardi syndrome.

Area of Science:

  • Neuropathology
  • Neurodevelopmental Disorders
  • Molecular Neuroscience

Background:

  • Pediatric epilepsy often presents with refractory seizures and developmental delays.
  • Astrocytic inclusions are distinctive pathological findings in certain neurological conditions.
  • Filamin A is a crucial actin-binding protein essential for neuronal migration.

Purpose of the Study:

  • To characterize unique astrocytic inclusions found in pediatric epilepsy patients.
  • To investigate the association of these inclusions with filamin A.
  • To explore a potential spectrum of neurological disorders involving filamin dysfunction.

Main Methods:

  • Pathological examination of cortical tissue from pediatric epilepsy patients.
  • Immunohistochemical analysis for filamin A.
  • Comparison with inclusions found in Aicardi syndrome cases.

Main Results:

  • Distinctive, eosinophilic, globular cytoplasmic inclusions were identified in cortical astrocytes.
  • These inclusions were exclusively immunopositive for filamin A.
  • Identical inclusions were previously characterized in Aicardi syndrome.

Conclusions:

  • The findings suggest a potential link between astrocytic filamin A inclusions and a spectrum of neurological disorders.
  • A new pathological entity, tentatively named "filaminopathy," is proposed.
  • Further research is needed to elucidate filamin A gene or protein aberrations in affected patients.

Related Concept Videos

Types of Intermediate Filaments01:31

Types of Intermediate Filaments

The intermediate filaments are an essential component of the cytoskeleton. Presently six types of intermediate filament have been identified. Type I and II are acidic and basic keratin proteins. Type III is of mesodermal origin and comprises four proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Vimentin is commonly found in mesenchymal cells, desmin in muscle cells, GFAP in astrocytes, while peripherin is found in peripheral nervous system neurons (PNS). Type...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...